SecBot SecBot

FULC

Fulcrum Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001680581 Biotech & Drug Discovery
$3.71 −0.06 (−1.59%)
Nov 16 4:00 PM ET · prev $3.77
Market cap
$281.1M
Micro cap
Median target
$4.00
+8% · range $3.00–4.00
1 year
−61.6%
from $9.65 · Nov 17
30 days
+0.3%
from $3.70
52-week range
$3.14–14.60
−75% from high · low Jun 2
Avg volume 20D
1.32M
shares / day
Short interest
6.44M
≈8.4% of shares · −4.7%
Days to cover
4.8
at average volume
Insider net
+$1.1M
1 buyer · 2 sellers · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
21
analyzed by SecBot
SecBot read MIXED 13 reports · 90 days
Balance 2 bearish · 0 bullish · 11 neutral oldest → newest, height = score
Avg score ·High conf. 10/13

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $1.5M at an average $3.56. 2 insiders sold $389.6K.

  • InstitutionsMIXED

    Q3 2026: 20 added (0 new), 16 trimmed or exited.

  • Short sellersSTEADY

    Short interest −4.7% to 6.44M shares. 4.8 days to cover, ≈8.4% of shares.

  • TrendRANGE

    1% below its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
BlackRock, Inc.ADD11,628,469$43.0M
RENAISSANCE TECHNOLOGIES LLCADD2,220,084$8.2M
MARSHALL WACE, LLPADD1,893,289$7.0M
STATE STREET CORPTRIM1,277,957$4.7M
FMR LLCDOUBLED659,776$2.4M
JANE STREET GROUP, LLCNEAR_EXIT522,521$1.9M
Jump Financial, LLCTRIM433,477$1.6M
MORGAN STANLEYADD332,097$1.2M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Last action Jun 2026
12-month targets · 3 analysts

Price is inside the target range. Median implies +8%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Jun 3, 2026JP Morgan
DOWNGRADE
DOWNGRADEUnderweight
Jun 2, 2026Stifel
DOWNGRADE
DOWNGRADEHold
Jun 2, 2026Piper Sandler
DOWNGRADE
DOWNGRADEUnderweight
Jun 2, 2026Truist Securities
DOWNGRADE
DOWNGRADEHold
Jun 2, 2026Leerink Partners
DOWNGRADE
DOWNGRADEMarket Perform
Jun 2, 2026HC Wainwright & Co.
DOWNGRADE
DOWNGRADENeutral

Insider ledger

Form 4
$1.5M
bought · 1 insider
$389.6K
sold · 2 insiders
+4.3%
vs their $3.56 cost
DateInsiderTypeValue
Jul 17, 2026
TANG KEVIN
10%+ Owner
Jul 17, 2026
BUY$179.3K
Jul 16, 2026
TANG KEVIN
10%+ Owner
Jul 16, 2026
BUY$415.3K
Jul 15, 2026
TANG KEVIN
10%+ Owner
Jul 15, 2026
BUY$382.3K
Jul 14, 2026
TANG KEVIN
10%+ Owner
Jul 14, 2026
BUY$271.9K
Jul 14, 2026
TANG KEVIN
10%+ Owner
Jul 14, 2026
BUY$191.0K
Jul 13, 2026
TANG KEVIN
10%+ Owner
Jul 13, 2026
BUY$45.9K
Jun 30, 2026
King Rachel K.
Director
Jun 30, 2026
AWARD32,000 sh
Jun 30, 2026
Gould Robert J
Director
Jun 30, 2026
AWARD32,000 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q-$0.36-$0.36–-$0.36-30.1%$0.00
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Washington

Corporate Lobbying

8 lobbying filings and 3 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 30, 2026
6,441,458
shares short
-4.7%
vs prior settlement
4.8
days to cover
≈8.4%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 13, 2026 SEC
Nantahala Capital Management disclosed a passive 8.62% stake in Fulcrum Therapeutics as of September 30, 2026, up from…
SC 13G/A · Impact 3/10
Oct 30, 2026 Earnings calendar
FULC Q3 2026 Earnings Scheduled · 2026-10-30
Sep 30, 2026 Inst.
BlackRock, Inc. · ADD
11,628,469 shares ($43.0M)
Sep 30, 2026 Inst.
RENAISSANCE TECHNOLOGIES LLC · ADD
2,220,084 shares ($8.2M)
Aug 17, 2026 Press
Fulcrum Therapeutics is being acquired by Slate Medicines in an all-stock reverse merger where pre-merger Fulcrum…
Impact 8/10
Jul 17, 2026 Insider
TANG KEVIN bought 50,945 shares
10%+ Owner @ $3.52 ($179.3K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent

SecBot reports

21 filings · 2 press releases · 3 bullish · 3 bearish · 2 mixed · 13 neutral
All FULC filing & press-release reports (23)